Bureau Veritas SA (0MH1)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 27.95 |
|---|---|
| 52-week range | 23.67 – 30.15 |
| Return, 1 month / 3 months | +2.5% / +3.2% |
| Return, 1 year / 3 years | +5.8% / +35.4% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 24.3% |
| Worst drawdown (1 year) | -13.8% |
| Average daily value traded | 9.45M EUR |
| Dividend yield | 3.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bureau Veritas provides testing, inspection and certification services to companies across many industries. Its work covers ships and marine equipment, construction and buildings, industrial facilities, consumer goods, food and agriculture, and energy. Clients use its inspections and audits to show that products, equipment and operations meet safety, quality and regulatory standards. The company is based in France and operates through a network of laboratories and offices in many countries, serving businesses, governments and public authorities.
The shares are listed on the London Exchange in UK under the code 0MH1, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bureau Veritas SA (0MH1) trades on the London Exchange in UK. It last closed at EUR 27.95 on 19 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 695 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 5.8% and over the last three months it rose 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.8% | ||
| From 52-week high | -5.1% | ||
| Momentum | 54 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.2% | ||
| 6-month return | 1.3% | ||
| 12-month return, skipping the last month | 3.3% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.8% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 9.45M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 3.3% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +2.6% |
|---|---|
| 1 month | +2.5% |
| 3 months | +3.2% |
| 6 months | +1.3% |
| 1 year | +5.8% |
| 3 years | +35.4% |
| 5 years | +19.9% |
Signals
| 50-day / 200-day average | 27.37 / 26.66 |
|---|---|
| Golden / death cross (60 days) | Golden, 58 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.47 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 May 2026 | EUR 0.9200 |
| 1 Jul 2025 | EUR 0.9000 |
| 2 Jul 2024 | EUR 0.8300 |
| 4 Jul 2023 | EUR 0.7700 |
| 5 Jul 2022 | EUR 0.5300 |
| 5 Jul 2021 | EUR 0.3600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.